Two Sigma Investments’s Aimmune Therapeutics AIMT Stock Holding History

Two Sigma Investments’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-152,876	Closed	-$5.27M	–	3945
2020 Q3	$5.27M	Sell	152,876 -13,980	-8%	-$298K	0.02%	773
2020 Q2	$2.79M	Sell	166,856 -120,919	-42%	-$2.05M	0.01%	936
2020 Q1	$4.15M	Buy	+287,775	New	+$7.36M	0.03%	586
2019 Q4	–	Sell	-130,645	Closed	-$2.74M	–	4128
2019 Q3	$2.74M	Buy	130,645 +7,408	+6%	+$151K	0.01%	1193
2019 Q2	$2.57M	Buy	+123,237	New	+$2.54M	0.01%	1274
2017 Q4	–	Sell	-10,100	Closed	-$250K	–	3579
2017 Q3	$250K	Buy	+10,100	New	+$218K	﹤0.01%	2509

Two Sigma Investments's AIMT Position: Q4 2020 in Review

Two Sigma Investments sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 152,876 shares — an estimated $5.27M sold.

Two Sigma Investments first reported a position in AIMT in Q3 2017 and held it in 6 quarters. The position peaked at $5.27M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Two Sigma Investments reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Two Sigma Investments sold 152,876 Aimmune Therapeutics shares in Q4 2020, an estimated $5.27M.
Two Sigma Investments first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 6 quarters.
Two Sigma Investments's Aimmune Therapeutics position peaked at $5.27M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Two Sigma Investments's 13F filing for Q4 2020, filed 16 Feb 2021.